Novozymes A/S Agrees to Acquire GroPep Limited
August 15, 2006
Novozymes A/S has proposed to acquire all issued securities of Australian biotech GroPep Limited via a scheme of arrangement, offering A$2.05 per share and valuing GroPep at approximately A$96 million. The transaction is subject to typical scheme and regulatory approvals, with completion expected by end of 2006, and is intended to expand Novozymes' biopharmaceutical/recombinant-ingredient capabilities and market access.
- Buyers
- Novozymes A/S
- Targets
- GroPep Limited
- Sellers
- GroPep share and option holders
- Industry
- Biotechnology
- Location
- South Australia, Australia
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Novotech to Acquire Agilex Biolabs from Healius to Expand Australian Bioanalytical Services
September 25, 2026
Healthcare Services
Novotech entered into an agreement to acquire Agilex Biolabs, an Adelaide-based Australian specialist bioanalytical laboratory business, from a wholly owned subsidiary of Healius. The deal is intended to expand Novotech’s laboratory capabilities in Australia and strengthen integrated clinical research and laboratory services for biotechnology and pharmaceutical clinical trial sponsors. Financial terms were not disclosed, and closing remains subject to customary regulatory conditions.
-
Novartis to Acquire MorphoSys in $2.9 Billion Deal
February 7, 2024
Pharmaceuticals
Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).
-
Biosynth Acquires Pepceuticals to Add Multi-Kilogram GMP Peptide Manufacturing
September 25, 2023
Pharmaceuticals
Biosynth has acquired Pepceuticals, a UK-based specialist in synthetic peptides with multi-kilogram GMP and fill-finish capabilities. The deal expands Biosynth’s peptide division and enables end-to-end support from discovery through clinical trials to commercial supply.
-
ADAMA Ltd. Acquires AgriNova New Zealand Ltd. (Grochem)
December 6, 2022
Agriculture
ADAMA Ltd. has acquired AgriNova New Zealand Ltd., trading as Grochem, a Wellington-based developer and manufacturer of crop protection products, plant growth regulators and biosolutions. The deal strengthens ADAMA's presence in New Zealand and expands its product capability into biologicals, plant nutrition and PGRs.
-
Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests
December 20, 2021
Healthcare Services
International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.
-
Novozymes Acquires Delta Biotechnology Ltd
July 12, 2006
Biotechnology
Novozymes A/S has acquired Delta Biotechnology Ltd from the sanofi-aventis group, making Delta a wholly owned subsidiary operating as Novozymes Delta Ltd. The acquisition expands Novozymes' capabilities in recombinant protein production and yeast-based expression systems to support growth in biopharmaceutical ingredient supply.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.